Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulgent Genetics, Inc. - Common Stock (NQ: FLGT )

17.00 -0.48 (-2.72%)
Streaming Delayed Price Updated: 10:36 AM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fulgent Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Fulgent Genetics to Announce Fourth Quarter and Full Year 2021 Financial Results on Wednesday February 23, 2022
From Fulgent Genetics, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
Via Benzinga
Corona Doom 3.0: Omicron Surge. Profiting From The Boom In COVID-19 Testing Due To The Omicron Wave
COVID testing in a parking garage in Miami on Tuesday (photo via Jordan Levin). Good Luck Getting Into A Medical Clinic A woman we know got in a car accident over the... 
Via Benzinga
Corona Doom 3.0: Omicron Surge
One of the beneficiaries of the COVID testing boom is Fulgent Genetics, Inc. 
Via Talk Markets
5 Value Stocks In The Healthcare Sector
What is a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
Is Fulgent Genetics a Good Healthcare Stock to Buy?
Shares fell earlier in the November, but popped again after a robust third-quarter earnings report. 
Via The Motley Fool
HelioLiver™, an Innovative Liquid Biopsy Test for the Early Detection of Liver Cancer, is Now Commercially Available
From Fulgent Genetics, Inc.
Via Business Wire
How Wide Is Fulgent Genetics' Moat?
The genetic testing company's moat is expanding. 
Via The Motley Fool
3 Stocks That Could Make You Richer in December (and Beyond)
Shares of these companies are gift-wrapped for those with patience. 
Via The Motley Fool
Topics Economy
Exposures COVID-19 Interest Rates
The Daily Biotech Pulse: Moderna, Pfizer-BioNTech Ink New Vaccine Deals With UK, GSK-Vir Antibody Show Activity Against Omicron, Chemomab Gets Clearance
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus U.K. Signs Deal to Buy Incremental COVID-19 Vaccines From Moderna And Pfizer-... 
Via Benzinga
Exposures COVID-19
Jim Cramer Weighs In On Carnival, Canadian Pacific Railway And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Fulgent Genetics, Inc. (NASDAQ: 
Via Benzinga
Fulgent Genetics Confirms Ability to Detect Omicron Variant with RT-PCR Tests for COVID-19
From Fulgent Genetics, Inc.
Via Business Wire
56 Biggest Movers From Friday
Gainers iSpecimen Inc. (NASDAQ: ISPC) climbed 71.7% to settle at $17.51 on Friday. The company recently announced it has been contracted to support new advanced research on... 
Via Benzinga
Is Fulgent Genetics Undervalued?
Whether Fulgent is a value or a value trap depends on the short-term prospects for COVID-19 and the long-term prospects for its core sequencing business. 
Via The Motley Fool
Exposures COVID-19
48 Stocks Moving In Friday's Mid-Day Session
Gainers Allied Healthcare Products, Inc. (NASDAQ: AHPI) shares jumped 68% to $9.04. Shares of mask and protective apparel companies, including Allied Healthcare Products, traded... 
Via Benzinga
3 Small-Cap COVID Stocks With Huge Upside
Three Fool.com contributors are bullish on Beyond Air, Ocugen, and Fulgent Genetics. 
Via The Motley Fool
Exposures COVID-19
The Monster Business Lurking Behind Fulgent's COVID Results
Fulgent's recent earnings report confirmed the strength of its core testing business. 
Via The Motley Fool
Exposures COVID-19
A Look Into Healthcare Sector Value Stocks
What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
How Is Fulgent Genetics Staying Ahead of Its Competition?
The key is by focusing on doctors. 
Via The Motley Fool
What Investors Should Like About Fulgent Genetics' Q3 Results
The genetic testing company delivered a solid performance in Q3. 
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Valneva (NASDAQ:VALN) shares increased by 24.51% to $50.34 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6... 
Via Benzinga
Fulgent Genetics Q3 Revenues More Than Double; Raises FY21 Outlook
Fulgent Genetics Inc (NASDAQ: FLGT) reported Q3 sales of $227.9 million, +124% Y/Y, beating the consensus of $264 million primarily driven by sales of its COVID-19... 
Via Benzinga
Fulgent Genetics, Inc. Common Stock (FLGT) Q3 2021 Earnings Call Transcript
FLGT earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Fulgent Genetics: Q3 Earnings Insights
Fulgent Genetics (NASDAQ:FLGT) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:00 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Fulgent Genetics Reports Third Quarter Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Representatives of Fulgent Genetics to Participate in Upcoming Virtual Conferences
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Genetics Launches At-Home Neutralizing Antibody Test for COVID-19
From Fulgent Genetics, Inc.
Via Business Wire
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.